May 6, 2008 -- Simcere Pharmaceutical Group (NYSE: SCR) released its first quarter financial report showing modestly higher revenues and a large increase in net profit. In Q1, Simcere booked revenues of 394 million RMB ($56.3 million), a solid increase of 26% from the year earlier period, and net income of 112 million RMB ($16 million), a much larger jump of 68%. The increases came from the company’s three first-to-market products. More details...
